Background Indacaterol is a long-acting inhaled β2-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

Highlights•Triple therapy in a single inhaler is a new therapeutic option for COPD.•Three
fixed dose combinations of inhaled corticosteroids LABA and LAMA are in Phase III of …

Objective: To assess the 24-h bronchodilator efficacy and safety of single-dose indacaterol
in asthma. Methods: This was a five-period, double-blind, double-dummy, crossover study in …

Chronic obstructive pulmonary disease (COPD) is increasing in the United States and
throughout the world. There have been a number of advances in the treatment of this …

Asthma treatment guidelines advocate the use of long-acting β2-agonists (LABA) in addition
to inhaled corticosteroids (ICS) in patients whose asthma is uncontrolled by ICS alone …

Asthma is a chronic inflammatory disorder of the airways that is a major global burden on
both individuals and healthcare systems. Despite guideline-directed treatment, a significant …

Long-acting muscarinic antagonists (LAMAs) have a recognised role in the management of
chronic obstructive pulmonary disease. In asthma, muscarinic antagonists (both short-and …

BACKGROUND: This study evaluated the dose-response and dosing interval of the novel
long-acting muscarinic receptor antagonist (LAMA) GSK573719 in patients with COPD …

Background: Use of a long-acting inhaled bronchodilator, either an anticholinergic or a β-
adrenergic receptor agonist (β-agonist), is recommended for maintenance treatment of …

GSK961081 is an inhaled bi-functional molecule with both muscarinic antagonism and β 2-
agonism (MABA) properties. This randomised, double-blind, double-dummy, crossover …